Dr. Inshad Ali Khan


Clinical Microbiology Division
CSIR - Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: iakhan[at]iiim[dot]res[dot]in, iakhan[at]iiim[dot]ac[dot]in, inshad[at]rediffmail[dot]com

Positions Held  
Position Held Date Organization
Principal Scientist 2010 - Present CSIR-IIIM
Senior Scientist 2006 - 2010 CSIR-IIIM
Scientist 2003 - 2006 CSIR-IIIM
Scientist Fellow 2002 - 2003 CSIR-IIIM
Research Scientist 2000 - 2002 NCER, Pune
Research Scientist 1996 - 2000 NDDR, Gurgaon
Honours & Awards  
  • NASI-Reliance Platinum Jubilee award-2017 for application oriented research in the area of biological sciences. 

  • Awarded DHR fellowship by Indian Council of Medical Research, India in March 2012 to work in NIAID, NIH, Maryland USA.

  • Cover page illustration of image in Journal of Medical Microbiology, May 2014, 63:763-766.
  • Qualified the Graduate Aptitude Test in Engineering (GATE) 1993 with a percentile score of 84.62 to avail UGC fellowship.
  • Life member of Indian Association of Medical Microbiologists (IAMM) since1994.
  • Life member of National Academy of Science of India (NASI)

  • Life member of National Academy of Medical Sciences (NAMS)

Major research areas:

  • Anti-infective research with reference to identification of novel scaffolds

Whole screening of large chemical libraries (50,000 compounds) against Mycobacterium tuberculosis has resulted in the identification of several novel scaffolds. The screening also employed streptomycin dependent M tuberculosis 18b which is absence of streptomycin behaves like non replicating latent M tb. We have now stated a medicinal chemistry program to work around the identified scaffolds to develop lead candidates.

  • Antimicrobial resistance and microbial efflux pumps

efflux pumps

Drug efflux is one of the major cause resistances in microorganisms. Our group is working bacterial trying to address the issue of emergence of drug resistance through efflux pumps inhibitors. We have a panel of efflux pumps overexpressing S aureus which are used to screen compound libraries and natural products as efflux pump inhibitors. We are also targeting the efflux pumps of Mycobacterium tuberculosis. One such putative pump (Rv1258c) has been over expressed in M. tuberculosis H37Rv and is employed in regular screening activities.

Efflux pump based combination under development

  1. Mupirocin + IIIM-1133 topical formulation with improved bioefficacy.

 Unique features of the lead

  1.   IIIM-1133 a novel piperine derived structure is a multiple bacterial efflux pump inhibitor
  2.   Blocks the emergence of resistance
  3.   A combination of IIIM-1133 with mupirocin exhibits better efficacy than the original mupirocin formulation.
  1. Rifampicin + IIIM-1132 combination for improved bioefficacy

Unique features of the lead

  1.  Potent human Pgp inhibitor
  2. Significantly enhance the PK of rifampicin (2.33 folds increase in Cmax and 1.62 folds increase in AUC of rifampicin).
  3.  The compound has good solubility (>5μM) under different test conditions and good permeability

    (ER ratio = 1.40) in Caco-2 cell lines.

  1.  No Cyp liabilities (Cyp 3A4 & Cyp 2D6) upto 10μM associated with the compound.

Better efficacy in combination with rifampicin and isoniazid in mouse model of TB infection.

Mupirocin + IIIM-1133 topical formulation with improved bioefficacy


Rifampicin + IIIM-1132 combination for improved bioefficacy


  • Target based drug discovery


GlmU GlmU

The N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU) enzyme is a 54.1 kDa bifunctional enzyme with both acetyltransferase and uridylyltransferase (pyrophosphorylase) activities that catalyses the following two step reaction

GlcN-1-P + AcCoA GlcNAc-1-P + CoA
GlcNAc-1-P + UTP UDP-GlcNAc + PPi

The product of the GlmU catalysed reactions, UDP-N-acetylglucosamine (UDP-GlcNAc), is a significant precursor for the peptidoglycan and LPS biosynthesis in Gram positive and Gram negative bacteria respectively. Our group has successfully cloned and expressed E.coli and M.tuberculosis GlmU and established 96 well format medium throughput assay.  About 50,000 compounds have been screed through whole cell and in-silico approaches and inhibitors have been identified.


Shikimate Kinase

Shikimate Kinase

The Shikimate pathway links metabolism ofcarbohydrates to biosynthesis of aromatic compounds through seven metabolic steps, where phosphoenolpyruvate and erythrose 4- phosphate are converted to chorismic acid. shikimate kinase of M. tuberculosis (MtSK) which catalyzes the fifth step in shikimate pathway where it converts shikimate to shikimate-3-phosphate using ATP as co-substrate (Figure1.). The aroK (Rv2539c) gene which is 531 base pairs long codes for 176 amino acids long Shikimate Kinase with a molecular mass of 18.58 kD. In M. tuberculosis, shikimate kinase is proven to be essential for the growth of microbe, as its disruption makes it unviable.

Shikimate Kinase

ATP synthase

ATP synthase is a ubiquitous key enzyme in energy metabolism of virtually all living cells. The enzyme utilizes the energy stored in a trans-membrane electrochemical potential difference of a coupling ion for production of ATP. Bacterial ATP synthase is composed of a membrane-embedded Fo sector with subunit composition a1b2c10–15 and a hydrophilic F1 part, consisting of subunits α3β3γδε. The assay system has been developed using the inverted membrane vesicles of M. smegmatis.

ATP synthase

  • Oral microbiology

Oral care activity is the major thrust area of the group. We have earlier worked on Proctor & Gamble and Colgate-Palmolive sponsored projects this area. We are looking for natural products based  on their activity on a panel of early, intermediate and late colonizers.

Oral microbiology

Lead: Chalcone compound as potentiator of triclosan’s activity


Click here for complete list.
  • Singh, S.; Kalia, N.P.; Joshi, P.; Kumar, A.; Sharma, P.R.; Kumar, A.; Bharate, S.B.; Khan, I.A. (2017) Boeravinone B, a novel dual inhibitor of NorA bacterial efflux pump of Staphylococcus aureus and human P-glycoprotein, reduced the biofilm formation and intracellular invasion of bacteria. Frontiers in Microbiology, (2017), (DOI: 10.3389fmicb.2017.01968).
  • Borkar, S.R.; Bokolia, N.; Aidhen, I.S.; Khan, I.A. Synthesis of threo- and erythro-configured trihydroxy open chain lipophilic ketones as possible anti-mycobacterial agents. Tetrahedron: Asymmetry. (2017), 28:186-195.
  • Ali, I.; Satti, N.K.; Dutt, P.; Prasad, R.; Khan, I.A. Hydroxychavicol: A phytochemical targeting cutaneous fungal infections. Scientific Reports, (2016) (DOI: 10.1038/srep37867).
  • Wani, N.A.; Singh, S.; Farooq, S.; Shankar, S.; Koul, S.;Khan, I.A.; Rai, R. Amino acid amides of piperic acid (PA) and 4-ethylpiperic acid (EPA) as NorA efflux pump inhibitors of Staphylococcus aureus Bioorganic and Medicinal Chemistry Letters (2016), 26:4174-4178.
  • Mehra, R.; Rani, C.; Mahajan, P.; RVishwakarma, R.A.; Khan, I.A.; Nargotra, A. Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro validation. ACS Combinatorial Science (2016),18:100-116.
  • Mehra, R.; Rajput, V.S.; Gupta, M.; Chib, R.; Kumar, A.; Wazir, P.; Khan, I.A.; Nargotra, A. Benzothiazole derivatives as a novel Mycobacterium tuberculosis shikimate kinase inhibitor: Identification and elucidation of its allosteric mode of inhibition. Journal of Chemical Information and Modelling (2016), 56:930-940.
  • Rajput, V.S.; Mehra, R.; Kumar, S.; Nargotra, A.; Singh, P.P.;Khan, I.A. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis. Applied Microbiology and Biotechnology (2016) 100(12):5415-5426.
  • Rani, C.;Khan, I.A. UDP-GlcNAc pathway: Potential target for inhibitor discovery against M. tuberculosis. European Journal of Pharmaceutical Sciences (2016) 83: 62-70
  • Sharma, R.; Lambu, M.R.; Jamwal, U.; Rani, C.; Chib, R.; Wazir, P.; Mukherjee, D.; Chaubey, A.; Khan, I.A. Escherichia coli N-Acetylglucosamine-1-Phosphate-Uridyltransferase/Glucosamine-1-Phosphate Acetyltransferase(GlmU) Inhibitory Activity of Terreic Acid Isolated from Aspergillus terreus. Journal of Biomolecular Screening (2016), 21(4): 342-353
  • Sharma, R.; Rani, C.; Mehra, R.; Nargotra, A.; Chib, R.; Rajput, V.S.; Kumar, S.; Singh, S.; Sharma, P.R.; Khan, I. A. Identification and characterization of Novel Small Molecule Inhibitors of the Acetyltransferase Activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Applied Microbiology and Biotechnology (2015) (DOI 10.1007/s00253-015-7123-y).

  • Yempalla, K.R.; Munagala, G.; Singh, S.; Kour, G.; Sharma, S.; Chib, R.; Kumar, S.; Wazir, P.; Singh, G.D.; Raina, S.; Bharate, S.S.; Khan, I. A.; Vishwakarm, R.A.; Singh, P.P. Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents ACS Medicinal Chemistry Letters (2015), 6: 1059-1064.

  • Yempalla, K.R.; Munagala, G.; Singh, S.; Magotra, A.; Kumar, S.; Rajput, V.S.; Bharate, S.S.; Tikoo, M.; Singh, G.D.; Khan, I. A.; Vishwakarm, R.A.; Singh, P.P. Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. ACS Medicinal Chemistry Letters (2015) 6: 1041-1046.

  • Rani,C.; Mehra,R. ; Sharma,R; Chib, R.; Wazir,P.; Nargotra,A. ; Khan,I. A.; . High- Throughput Screen Identifies Small Molecule Inhibitors Targeting Acetyltransferase Activity of Mycobacterium tuberculosis GlmU. Tuberculosis (2015), (Doi: 10.1016/j.tube.2015.06.003)

  • Munagala,G.; Yempalla, K. R.; Singh,S.; Sharma, S.; Kalia,N. P.; Rajput,V.S.; Kumar,S.; Sawant,S. D. ; Khan,I.A.; Vishwakarma,R. A. ; Singh,P. P. Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3- dihydroimidazooxazoles as anti-TB agents: in vitro, structure–activity relationship, pharmacokinetics and in vivo evaluation Organic & Biomolecular Chemistry.(2015), 13: 3610-3624.

  • Mehra,R.; Sharma,R.; Khan,I.A.; Nargotra,A.Identification and optimization of Escherichia coli GlmU inhibitors: An in silico approach with validation thereof. European Journal of Medicinal Chemistry (2014), 92:78-90.

  • Joshi,P.; Singh,S.; Wani,A.; Sharma,S.; Jain,S.,K. ; Singh,B.; Gupta,B. D.; Satti,N. K.; Koul,S.; Khan,I.A.; Kumar,A. ; Bharate,S. B.; Vishwakarma ,R.A. Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: Reversing the resistance against frontline antibacterial drugs MedChem Comm (2014) , 5:1540-1547.

  • Sharma,S.; Kalia,N.P. ; Suden,P. ; Chauhan, P.S.; Kumar,M.; Ram,A. B.; Khajuria,A.; Bani,S.; Khan,I. A. Protective efficacy of piperine against Mycobacterium tuberculosis.  Tuberculosis (2014),94: 389-396.

  • Kumar, A.; Khan,I.A.; Sharma,P. R.; Sumathy,K.; Ella ,K. M. Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant Staphylococcus aureus from Indian hospitals. Journal of Medical Microbiology (2014),63:763-766.

  • Gurunadham,M.; Yempalla,K.R.; Aithagani,S. K. ; Kalia, N.P; Ali,F.; Ali,I.; Rajput , V. S.;Rani,C.. ; Chib,R.; Mehra, R.; Nargotra,Amit.; Khan,I.A. ; Vishwakarma,R.A.; Singh,P.P.Synthesis and Biological Evaluation of Substituted N-Alkylphenyl-3, 5-Dinitrobenzamide Analogs as Anti-TB Agents. MedChemComm(2014), 5: 521-527.

  • Kalia, NP.; Mahajan ,P.; Nargotra, A.;Sharma ,JP.; Koul ,S.; Khan, IA. Capsaicin, a novel inhibitor of NorA efflux pump reduces the intracellular invasion of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy(2012), 67: 2401–2408.

  • Ali ,F.; Sangwan ,PL.; Koul ,S.; Pandey ,A.; Bani, S.; Abdullah ,ST.; Sharma ,PR.; Kitchlu, S.; Khan, IA. 4-epi-Pimaric acid: A phytomolecule as a potent antibacterial and anti–biofilm agent for oral cavity pathogens European Journal of Clinical Microbiology and Infectious Diseases.(2012), 31: 149-159.

  • Mirza, ZM.; Kumar, A.; Kalia, NP.; Zargar, A.; Khan, IA. Piperine as an inhibitor of MdeA efflux pump of Staphylococcus aureus. Journal of Medical Microbiology(2011), 60:1472-1478.

  • Ali ,I.; Sharma, P.; Suri, KA.; Satti, NK.; Dutt, P.; Afrin, F.; Khan, IA. In vitro antifungal activities of amphotericin B in combination with acteoside, a phenylethanoid glycoside from Colebrookea oppositifolia. Journal of Medical Microbiology (2011),60: 1326-1336.

  • Kumar, M.; Khan, F.G.; Sharma, S.; Kumar, R.; Faujdar, J.; Sharma, R.;, Chauhan, D.S.; Singh, R.; Magotra ,S.K. ; Khan, I.A. Identification of Mycobacterium tuberculosis genes uniquely expressed in tuberculosis patients.  Microbial pathogensis (2010) 50: 31-38.

  • Sharma, S.; Kumar, M.; Sharma, S.; Nargotra, A.; Koul, S.; Khan, I.A. Piperine as inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy (2010)65: 1694-1701.

  • Ali, I.; Khan, F.G.; Suri, K.A.; Gupta, B.D.; Satti, N.K.; Dutt, P.; Afrin, F.; Qazi, G.N.; Khan, I.A. In-vitro antifungal activity of hydroxychavicol isolated from Piper betle L. Annals of Clinical Microbiology and Antimicrobials(2010), 9: 7.

  • Sharma, S.;  Khan,I.A.; Ali,I. ; Ali,F.; Kumar,M.; Kumar,A.; Johri,R.K.; Abdullah,S.T.; Bani,S. ; Pandey, A.; Suri,K.A.;Gupta, B.D. ; Satti,N.K.; Dutt ,P. ; Qazi,G.N. Evaluation of hydroxychavicol for its antimicrobial, antioxidant and anti-inflammatory activity for its potential use as oral care agent. Antimicrobial Agents and Chemotherapy (2009),53(1): 216-222.

  • Kumar, A.; Khan, I.A.; Koul ,S.; Koul, J.L.; Taneja, S.C.; Ali, I.; Ali, F.; Sharma, S.; Mirza, Z.M.; Kumar, M.; Sangwan, P.L.; Gupta, P.; Thota, N.; Qazi G.N. Novel structural analogues of piperine as inhibitors of NorA efflux pump of Staphylococccus aureus. Journal of  Antimicrobial Chemotherapy  (2008),61:1270–1276.

  • Khan, I.A.; Mirza, Z.M.; Kumar,A. ; Verma, V.; Qazi,Q.N. Piperine, A Phytochemical Potentiator of Ciprofloxacin against Staphylococcus aureus. Antimicrobial  Agents Chemotherapy (2006),50(2): 810-812.

  • Kumar,Manoj.; Khan,I. A.; Verma,V.; Kalyan,N.; Qazi,G. N. Rapid, Inexpensive  MIC determination  of  Mycobacterium tuberculosis by using Microplate Nitrate Reductase Assay. Diagnostic Microbiology and Infectious Diseases (2005),53: 121-124.

  • Kumar,Manoj.;Khan, I.A.;Verma,V.; Qazi,G.N. Microplate nitrate Reductase assay versus alamar blue assay for MIC Determination of Mycobacterium tuberculosis.  International Journal of Tubercle and Lung Diseases.(2005), 9(8): 939-941.

  • Khan, I.A.; Rattan, A; Fatma ,T.; Khan, F.G.; Kalia, A. Application of whole cell protein analysis by SDS PAGE to establish the source of Salmonella typhimurium . Journal of Infection (1996) , 33: 69-171.


  • Singh, P. P.;  Kushalava,R. Y.; Munagala,G.; Sumit ,S.;  Khan, I. A.; Singh,S.; Vishwakarma,R. A. Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b] oxazole as anti-mycobacterial agents and a process for preparation there of (US Patent application, 3009/DEL/2014 dated 21-10-2014).

  • Singh, P. P.; Munagala, G.; Kushalava,R.Y.; Khan,I. A.; Kalia, N. P.; Singh ,V. R.; Nargotra, A.; Sawant,S. D.; Vishwakarma,Ram Aarey. 6-Nitro-2,3-dihydroimidazo[2,1-b] oxazoles and a process for the preparation thereof. (0225NF2012, PCT/IN2014/000202 dated March 31, 2014).

  • Vishwakarma, R.;  Kumar, A.; Khan, I. A.; Bharate, S. B.; Joshi, P.; Singh ,S.; Satti ,N. Benzopyrano[3,4-b][1]benzopyran-12(16H)-ones as bacterial efflux pump and human p-glycoprotein efflux pump inhibitors. (0036NF2014 dated: 30th January 2014, 3077DEL2014).

  • Koul,S.; Reddy,V. M .; Sangwan,P.L.; Singh,B.; Kumar,C. P.; Khan,I. A.;Kalia, N. P.; Vishwakarma,Ram. Novel diaamides as potentiators of bioefficacy of drugs. (US patent applied NF 042 Feb2011, 864DEL 2011).

  • Ahmed, K.; Arutla ,V.; Chandra M.;,Jayanti, N. S..; Sultana,F.; Ramakrishna,G.; Khan,I. A.; Kalia,N.P. Phenyl nitrofurfuryl linked piperidino-oxadiazolone conjugates as anti-tubercular agents and process for the preparation thereof. (US patent applied 2011).

  • Kamal, A.;  Shetti, V.C.R.N.C.R.;  Swapna, P.;  Shaik Azeeza, S.; Reddy, A.M.; Khan, I.A.; Abdullah, S.T.; Sharma, S.;  and  Kalia, N.P.; Synthesis of benzothiazole derivatives as potential anti-tubercular agents. (US2012/0095021 A1 published on 19-04-2012).

  • Kamal, A.; Azeeza, S.; Ali, S.A.; Shaheer, M.M.; Khan, I.A.; Abdullah, S.T.; Sharma, S.; and Ram, A.B.; A process for the synthesis of new quinolylpiperazino substituted congeners of thiolactomycin as anti-tubercular antibiotics. (filled on 06-05-2010, WO 2011/138666 A1 granted on 10-11-2011).

  • Subramanyam, R..;Du Thumm , L.; Qazi, G.N.; Khan I.A.; Suri, K.A.; Satti, N.K.; Ali, F.; Kalia, N.P. Chalcones as Enhancer of Antimicrobial Agents. (filled on 18-12-2009 WO /2011/075136 A1, granted on 23-06-2011).

  • Jorge, C.S.; Mathias, H.; Qazi, G.N.; Khan, I.A.; Suri, K.A.; Satti, N.K. Substrate impregnated with a composition comprising hydroxychavicol. (filled on 14-11-2008 ,US patent applied, 2579DEL-2008).

  • Koul S.; Reddy M. V.;  Thota N.;  Koul J. L.; Sangwan P. L.; Taneja S. C.;  Khan, I. A.; Kumar, A.; Kalia, N. P.; Abdullah T. S.;  Johri R. K.; Pagoch S. S.;  Tikoo A. K.; Tikoo M. K.;  Saxena A. K.; Agrawal S. K.;  Mondhe D. M.; Purnima B.; Sharma S.,  Singh S.; Singh G. D.;  Bhusari S.; Qazi G. N. Novel aromatic amides as potentiators of bioefficacy of drugs. (2496DEL2010).

  • Koul, S.; Niranjan, T.; Reddy, M.V.; Sangwan, P.L.; Taneja, S.C.; Khan, I.A.; Kumar, A.; Raja, A.F.; Saxena, A.K.; Agrawal, S.K.; Johri, R.K.; Abdullah, T.S.; Singh, G.; Rao, B.L.N.; Dhar, A.K.; Purnima, B.; and Qazi, G.N. Preparation of novel efflux pump inhibitors. (filed on 05-03-2008, WO/2009/110002 granted on 11-09-2009).

  • Kaul, A.; Bani, S.; Suri, K.A.; Satti, N.; Kapahi, B. K.; Gupta, V. K.; Khan, I.A.; Khan, B.; Dutt, P.; Ali, I.; Sehar I.; and Qazi, G. N. Plumieride: an immunostimulating agent from Plumeria rubra leaves. (0775DEL2010).

  • Koul, S.; Koul, J. L.; Taneja, S. C.; Gupta, P.; Khan, I. A.; Mirza, Z. M.; Kumar, A.; Johri, R. K.; Pandita, M.; Khosa, A.; Tikko, A. K.; Sharma, S. C.; Verma, V.; and Qazi, G. N. 2006. Aromatic amides as potentiators of bioefficacy of anti-infective drugs (filled on 29-03-2006 WO 2006/103527 granted on 05-10-2006).

  • Qazi, G.N.; Singh, J.; Malik, F.; Saxena, A.K.; Suri, K.A.; Satti, N.K.; Kumar, A.; Kumar, A.; Bhushan, S.; Khan, I.A.; Mondhe, D.M.; Muthiah, S.; Chandra, H.; Gupta, A.; Kumar, M.; Sharma, S.; and Singh, S. “A synergistic formulation from Withania Somnifera useful for anti-cancer and TH1 dominant immune up-regulating activities”. (1321DEL2007).

  • Qazi, G.N.; Suri, O.P.; Bedi, K.L.; Khan, I.A.; Verma, V.; Johri, R.K.; Suri, K.A.; Gupta, B.D.; Satti, N.K.; Tikoo, M.K.; Sharma, S.C.; and Tikoo, A.K. Use of herbal agents as potentiators of anti infectives (filed on 31-03-2003, US patent no. 7119075 granted on 10-10-2006)

Current Students

Naveen Bokolia

Sukirti Sharma

Smriti Sharma

Diksha Raina

Alumni     Thesis Title Year

Dr. Manoj Kumar

(Associate Professor, Apeejay Stya University Research Centre, Gurgaon)
Identification of in-vivo expressed antigens of Mycobacterium tuberculosis in HIV positive TB patients using IVIAT. 2009

Dr. Ashwani Kumar

(Sr. Research Scientist, NDD, Biology Drug Discovery Wockhardt, Aurangabad)
Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. 2010

Dr. Zahid Mehmood Mirza

(Sr Tech Asst, SMVDU, Katra, Jammu)
Synergistic interaction of piperine with mupirocin against Staphylococcus aureus  infection 2011

Dr. Intzar Ali

(Post Doc, School of Life Sciences, JNU, New Delhi)
Plant derived molecules as potential antifungal agents. 2011

Dr. Sandeep Sharma

(Associate Prof, Arni University, Himachal Pradesh)
Piperine as bioefficacy enhancer of rifampicin against Mycobacterium tuberculosis infection. 2011

Dr. Furqan Ali

(Research Scientist, Sami Labs, Bangalore)
Evaluation of plant derived molecules as oral care agents and elucidation of their mechanism of action. 2012

Dr. Nitin Pal Kalia

(Post Doc, NTU, Singapore)
Evaluation of Capsaicin and its structural analogs as multidrug  efflux pump inhibitors of Staphylococcus aureus. 2014

Dr. Rukmankesh Mehra

(Postdoctoral Fellow, Denmark Technical University)
Discovery of new inhibitors of therapeutically validated bacterial targets by applying molecular modeling techniques. 2016

Dr. Chitra Rani

(NPF, Department of Biophysics, AIIMS, New Delhi)

Identification of small molecule inhibitors of N- acetylglucosamine-1-phosphate uridyltransferase(GlmU) in Mycobacterium tuberculosis. 2016

Dr. Vikrant Singh Rajput

(Young Scientist, School of Biotechnology, JNU)

Identification of inhibitors of Shikimate Kinase of Mycobacterium  tuberculosis.


Dr. Rashmi Sharma

(SERB-Indo-US fellow, Infectious Disease Research Institute (IDRI), Seattle, USA)

“Identification of small molecule inhibitors of the acetyltransferase domain of N acetylglucosamine-1-phosphate-uridyltransferase/ glucosamine-1-phosphate acetyltransferase (GlmU).

BSL-3 facility
Aerosol infection system for TB infection in rodents
Gel Documentation system
Walk in cold room and deep freezer facility